Parenchymal-Sparing Surgery for the Surgical Treatment of Multiple Colorectal Liver Metastases Is a Safer Approach than Major Hepatectomy Not Impairing Patients' Prognosis: A Bi-Institutional Propensity Score-Matched Analysis

Matteo Donadon, Matteo Cescon, Alessandro Cucchetti, Matteo Cimino, Guido Costa, Benedetta Pesi, Giorgio Ercolani, Antonio Daniele Pinna, Guido Torzilli

Research output: Contribution to journalArticle

Abstract

Background: The performance of parenchymal-sparing hepatectomy (PSH) versus major hepatectomy (MH) in patients with multiple colorectal liver metastases (CLM) is a matter that is yet debated. We investigated the outcome of patients with multiple CLM undergoing PSH instead of MH. Methods: Databases at 2 institutions were reviewed. A propensity score-matched analysis was applied. Among 554 patients, 110 undergoing PSH and 110 undergoing MH were matched. They were similar in baseline characteristics, comorbidity, and tumor features. Primary outcomes were short- and long-term outcomes. Results: Morbidity was significantly higher in the MH group, while mortality was not significantly different. There were no differences in free-margins width, but a trend of increased survival was seen in the PSH group with a median advantage of 6 months over the MH group. Among the prognostic factors, the T status (hazard ratio [HR] 2.6; p = 0.001), the N status (HR 2.9; p = 0.001), the timing of CLM diagnosis (HR 2.1; p = 0.002), the tumor number (HR 2.0; p = 0.001), the tumor size (HR 2.2; p = 0.015), and the neo-adjuvant chemotherapy (HR 1.7; p = 0.023) were found to be statistically and independently significant for survival. Conclusions: PSH conveys advantage over MH in terms of decreased postoperative morbidity, and a trend of survival benefit. PSH should be considered a suitable alternative to MH whenever it is technically feasible.

Original languageEnglish
JournalDigestive Surgery
DOIs
Publication statusAccepted/In press - Oct 14 2017

Fingerprint

Propensity Score
Hepatectomy
Neoplasm Metastasis
Liver
Therapeutics
Survival
Morbidity
Neoplasms
Adjuvant Chemotherapy
Comorbidity

Keywords

  • Colorectal liver metastases
  • Colorectal tumors
  • Hepatectomy
  • Major hepatectomy
  • Parenchymal-sparing hepatectomy

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

@article{87c063606c594e44a5e13d35b245322e,
title = "Parenchymal-Sparing Surgery for the Surgical Treatment of Multiple Colorectal Liver Metastases Is a Safer Approach than Major Hepatectomy Not Impairing Patients' Prognosis: A Bi-Institutional Propensity Score-Matched Analysis",
abstract = "Background: The performance of parenchymal-sparing hepatectomy (PSH) versus major hepatectomy (MH) in patients with multiple colorectal liver metastases (CLM) is a matter that is yet debated. We investigated the outcome of patients with multiple CLM undergoing PSH instead of MH. Methods: Databases at 2 institutions were reviewed. A propensity score-matched analysis was applied. Among 554 patients, 110 undergoing PSH and 110 undergoing MH were matched. They were similar in baseline characteristics, comorbidity, and tumor features. Primary outcomes were short- and long-term outcomes. Results: Morbidity was significantly higher in the MH group, while mortality was not significantly different. There were no differences in free-margins width, but a trend of increased survival was seen in the PSH group with a median advantage of 6 months over the MH group. Among the prognostic factors, the T status (hazard ratio [HR] 2.6; p = 0.001), the N status (HR 2.9; p = 0.001), the timing of CLM diagnosis (HR 2.1; p = 0.002), the tumor number (HR 2.0; p = 0.001), the tumor size (HR 2.2; p = 0.015), and the neo-adjuvant chemotherapy (HR 1.7; p = 0.023) were found to be statistically and independently significant for survival. Conclusions: PSH conveys advantage over MH in terms of decreased postoperative morbidity, and a trend of survival benefit. PSH should be considered a suitable alternative to MH whenever it is technically feasible.",
keywords = "Colorectal liver metastases, Colorectal tumors, Hepatectomy, Major hepatectomy, Parenchymal-sparing hepatectomy",
author = "Matteo Donadon and Matteo Cescon and Alessandro Cucchetti and Matteo Cimino and Guido Costa and Benedetta Pesi and Giorgio Ercolani and Pinna, {Antonio Daniele} and Guido Torzilli",
year = "2017",
month = "10",
day = "14",
doi = "10.1159/000479336",
language = "English",
journal = "Digestive Surgery",
issn = "0253-4886",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Parenchymal-Sparing Surgery for the Surgical Treatment of Multiple Colorectal Liver Metastases Is a Safer Approach than Major Hepatectomy Not Impairing Patients' Prognosis

T2 - A Bi-Institutional Propensity Score-Matched Analysis

AU - Donadon, Matteo

AU - Cescon, Matteo

AU - Cucchetti, Alessandro

AU - Cimino, Matteo

AU - Costa, Guido

AU - Pesi, Benedetta

AU - Ercolani, Giorgio

AU - Pinna, Antonio Daniele

AU - Torzilli, Guido

PY - 2017/10/14

Y1 - 2017/10/14

N2 - Background: The performance of parenchymal-sparing hepatectomy (PSH) versus major hepatectomy (MH) in patients with multiple colorectal liver metastases (CLM) is a matter that is yet debated. We investigated the outcome of patients with multiple CLM undergoing PSH instead of MH. Methods: Databases at 2 institutions were reviewed. A propensity score-matched analysis was applied. Among 554 patients, 110 undergoing PSH and 110 undergoing MH were matched. They were similar in baseline characteristics, comorbidity, and tumor features. Primary outcomes were short- and long-term outcomes. Results: Morbidity was significantly higher in the MH group, while mortality was not significantly different. There were no differences in free-margins width, but a trend of increased survival was seen in the PSH group with a median advantage of 6 months over the MH group. Among the prognostic factors, the T status (hazard ratio [HR] 2.6; p = 0.001), the N status (HR 2.9; p = 0.001), the timing of CLM diagnosis (HR 2.1; p = 0.002), the tumor number (HR 2.0; p = 0.001), the tumor size (HR 2.2; p = 0.015), and the neo-adjuvant chemotherapy (HR 1.7; p = 0.023) were found to be statistically and independently significant for survival. Conclusions: PSH conveys advantage over MH in terms of decreased postoperative morbidity, and a trend of survival benefit. PSH should be considered a suitable alternative to MH whenever it is technically feasible.

AB - Background: The performance of parenchymal-sparing hepatectomy (PSH) versus major hepatectomy (MH) in patients with multiple colorectal liver metastases (CLM) is a matter that is yet debated. We investigated the outcome of patients with multiple CLM undergoing PSH instead of MH. Methods: Databases at 2 institutions were reviewed. A propensity score-matched analysis was applied. Among 554 patients, 110 undergoing PSH and 110 undergoing MH were matched. They were similar in baseline characteristics, comorbidity, and tumor features. Primary outcomes were short- and long-term outcomes. Results: Morbidity was significantly higher in the MH group, while mortality was not significantly different. There were no differences in free-margins width, but a trend of increased survival was seen in the PSH group with a median advantage of 6 months over the MH group. Among the prognostic factors, the T status (hazard ratio [HR] 2.6; p = 0.001), the N status (HR 2.9; p = 0.001), the timing of CLM diagnosis (HR 2.1; p = 0.002), the tumor number (HR 2.0; p = 0.001), the tumor size (HR 2.2; p = 0.015), and the neo-adjuvant chemotherapy (HR 1.7; p = 0.023) were found to be statistically and independently significant for survival. Conclusions: PSH conveys advantage over MH in terms of decreased postoperative morbidity, and a trend of survival benefit. PSH should be considered a suitable alternative to MH whenever it is technically feasible.

KW - Colorectal liver metastases

KW - Colorectal tumors

KW - Hepatectomy

KW - Major hepatectomy

KW - Parenchymal-sparing hepatectomy

UR - http://www.scopus.com/inward/record.url?scp=85031812858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031812858&partnerID=8YFLogxK

U2 - 10.1159/000479336

DO - 10.1159/000479336

M3 - Article

C2 - 29032372

AN - SCOPUS:85031812858

JO - Digestive Surgery

JF - Digestive Surgery

SN - 0253-4886

ER -